Markus Fendt Selected Research

Orexins

1/2022	Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment.
1/2021	Orexin deficiency affects sociability and the acquisition, expression, and extinction of conditioned social fear.
1/2017	Increased anxiety but normal fear and safety learning in orexin-deficient mice.
3/2014	Behavioral analysis of narcoleptic episodes in orexin-deficient mice.
12/2012	The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
9/2011	Narcoleptic episodes in orexin-deficient mice are increased by both attractive and aversive odors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markus Fendt Research Topics

Disease

8	Anxiety Disorders (Anxiety Disorder) 05/2021 - 01/2020
6	Narcolepsy 01/2017 - 09/2011
4	Cataplexy 01/2017 - 09/2011
4	Sleep Initiation and Maintenance Disorders (Insomnia) 10/2015 - 01/2013
3	Mental Disorders (Mental Disorder) 05/2021 - 01/2020
2	Schizophrenia (Dementia Praecox) 01/2022 - 01/2021
2	Sleep Wake Disorders 10/2013 - 01/2013
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2022
1	Wounds and Injuries (Trauma) 01/2021
1	Central Nervous System Infections (Central Nervous System Infection) 09/2020
1	Gliosis 01/2017
1	Disorders of Excessive Somnolence (Hypersomnia) 01/2017
1	Alzheimer Disease (Alzheimer's Disease) 01/2017
1	Memory Disorders (Memory Loss) 01/2017
1	Neuroinflammatory Diseases 01/2017
1	Phobic Disorders (Phobia) 01/2016
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2016
1	Epilepsy (Aura) 10/2015
1	Psychotic Disorders (Schizoaffective Disorder) 10/2015
1	Inflammation (Inflammations) 10/2015
1	Pain (Aches) 10/2015
1	Parkinson Disease (Parkinson's Disease) 11/2011
1	Shock 02/2004

Drug/Important Bio-Agent (IBA)

6	OrexinsIBA 01/2022 - 09/2011
3	almorexantIBA 10/2013 - 12/2012
2	NeuropeptidesIBA 01/2020 - 01/2020
2	Orexin Receptor AntagonistsIBA 10/2013 - 01/2013
2	suvorexantIBA 10/2013 - 01/2013
2	Orexin ReceptorsIBA 10/2013 - 01/2013
1	Oxytocin (Pitocin)FDA LinkGeneric 05/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021
1	Viral RNAIBA 09/2020
1	human neuropeptide SIBA 01/2020
1	Hormones (Hormone)IBA 01/2020
1	methysticinIBA 01/2017
1	CytokinesIBA 01/2017
1	Interleukin-17 (Interleukin 17)IBA 01/2017
1	Antidepressive Agents (Antidepressants)IBA 01/2016
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	Serotonin (5 Hydroxytryptamine)IBA 01/2016
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2015
1	Modafinil (Provigil)FDA Link 01/2015
1	Pharmaceutical PreparationsIBA 08/2014
1	ErgolinesIBA 08/2014
1	Histamine H3 Receptors (Histamine H3 Receptor)IBA 08/2014
1	MK-6096IBA 01/2013
1	N- ((1- ((5- (4- fluorophenyl)- 2- methyl- 4- thiazolyl)carbonyl)- 2- piperidinyl)methyl)- 4- benzofurancarboxamideIBA 01/2013
1	SynucleinsIBA 11/2011
1	Dopamine (Intropin)FDA LinkGeneric 11/2011
1	MuscimolIBA 02/2004

Therapy/Procedure

4	Therapeutics 05/2021 - 01/2020
1	Oral Administration 01/2017
1	Traditional Medicine (Folk Remedies) 10/2015
1	Injections 02/2004